**Annex 2:**

**Asthma Control**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Asthma control (N=153)** | | |
| ***Controlled***  ***N1(%)*** | ***Partly controlled***  ***N2(%)*** | ***Uncontrolled***  ***N3(%)*** |
| Enrollment | 30 (19.6) | 70 (45.8) | 53 (34.6) |
| 1st follow up visit | 119 (77.8) | 30 (19.6) | 4 (2.6) |
| 2nd follow up visit | 123 (80.4) | 26 (17) | 4 (2.6) |
| 3rd follow up visit | 133 (86.9) | 17 (11.1) | 3 (2) |
| Outcome | 88 (57.5) | 65 (42.5) | 0 |

**Medication used during the study**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Medication (N=153)** | | | |
| ***No***  ***N1(%)*** | ***Montelukast***  ***N2(%)*** | ***Fluticasone***  ***N3(%)*** | ***Montelukast + Fluticasone***  ***N4(%)*** |
| Enrollment | 27(17.6) | 30 (19.6) | 55 (35.9) | 41 (26.8) |
| 1st follow up visit | 2 (1.3) | 27 (17.6) | 86 (56.2) | 38 (24.8) |
| 2nd follow up visit | 1 (0.65) | 26 (17) | 88 (57.5) | 38 (24.8) |
| 3rd follow up visit | 2 (1.3) | 25 (16.3) | 92 (60.1) | 34 (22.2) |

**Missing medication use**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Missing medication use (N=153)** | | |
| ***0 day***  ***N1(%)*** | ***1-2 days***  ***N2(%)*** | ***≥ 3 days***  ***N3(%)*** |
| 1st follow up visit | 138 (90.2) | 7 (4.6) | 8 (5.2) |
| 2nd follow up visit | 141 (92.2) | 8 (5.2) | 4 (2.6) |
| 3rd follow up visit | 142 (92.8) | 7 (4.6) | 4 (2.6) |

**Regularity of follow up visits**

|  |  |  |
| --- | --- | --- |
|  | **Regularity (N=153)** | |
| ***Regularly*** | ***Irregularly (> 1week late)*** |
| 1st follow up visit | 119 (77.8) | 34 (22.2) |
| 2nd follow up visit | 105 (68.6) | 48 (31.4) |
| 3rd follow up visit | 106 (69.3) | 47 (30.7) |

**Technique using medication (MDI plus spacer device)**

|  |  |  |
| --- | --- | --- |
|  | **Technique (N=153)** | |
| ***Correct*** | ***Incorrect*** |
| 1st follow up visit | 148 (96.7) | 34 (3.3) |
| 2nd follow up visit | 148 (96.7) | 48 (3.3) |
| 3rd follow up visit | 151 (98.7) | 47 (1.3) |